生物制药公司Akebia Therapeutics（股票代码：AKBA）在周三盘后交易中股价大幅下跌20.77%，引发投资者关注。这一显著跌幅主要源于公司宣布的新股发行计划。
据报道，Akebia Therapeutics已开始进行股票发行，尽管具体交易规模尚未披露。Leerink Partners和Piper Sandler将担任此次发行的联合账簿管理人。这一融资举措可能会稀释现有股东的股权，因此引发了市场的负面反应。值得注意的是，在此消息公布之前，AKBA股价曾连续四个交易日上涨，累计涨幅高达68%，周三常规交易时段更是上涨11.4%收于2.84美元。
尽管股价出现大幅下跌，但Akebia Therapeutics的业务前景似乎仍然积极。上周四，公司曾预计其贫血药物Vafseo在第一季度将实现1000万至1100万美元的净产品收入。这一预期显示了公司核心产品的市场潜力。然而，新股发行计划的公布暂时盖过了这一利好因素，导致投资者情绪转向谨慎。随着更多关于股票发行的细节公布，市场将密切关注Akebia Therapeutics的后续发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.